Invention:
This technology is directed to an antibody to a mutated endoglin protein. Specifically, this antibody provides methods and compositions for detecting splice variants of the endoglin protein, enabling the accurate diagnosis of cancer. This invention further includes the use of endoglin-specific antibodies to enhance the detection process, offering a more precise and reliable approach to identifying cancer-related variants of endoglin.
Background:
According to the American Cancer Society, pancreatic cancer accounts for about 3% of all cancers in the United States and about 7% of all cancer deaths. The need for a new pancreatic biomarker with increase efficiency is more necessary than ever as traditional methods fail to properly determine susceptibility and overall predictability. This innovation features two novel sequences of an endoglin protein for use a new biomarker for pancreatic cancer determination.
Applications:
- Novel endoglin protein biomarker for pancreatic cancer
Advantages:
- Two novel sequences
- Increased efficiency in cancer prediction
- Use of endoglin protein
